Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2

J Exp Med. 1982 Aug 1;156(2):385-97. doi: 10.1084/jem.156.2.385.


We have studied the ability of immunized lymphoid cells expanded in IL-2 to mediate the cure of mice with localized and disseminated syngeneic lymphoma. Mice received 500 rad total-body irradiation before injection of tumor into the footpad. Mice were treated 5 d later when a palpable local tumor and disseminated metastases were present. Intravenous injection of in vivo immune lymphocytes cured 93% of all mice, significantly better than any control group (P less than 0.0005). Immune cells, secondarily sensitized to the FBL-3 tumor in vitro, also conferred significant survival benefit (P less than 0.005) when injected intravenously, curing 79% of the animals treated. When these in vitro sensitized cells were expanded in IL-2, 8-10-fold over 7 d, 93% of the animals thus treated were cured, (P less than 0.005). When these cells were grown for multiple generations in IL-2 they retained their ability to cure mice (56% cured, P less than 0.01). This is the first demonstration that intravenous injection of sensitized cells grown in long term culture in IL-2 is capable of curing mice of established local and disseminated syngeneic tumor.

MeSH terms

  • Animals
  • Cell Survival
  • Cytotoxicity, Immunologic
  • Female
  • Fibrosarcoma / immunology
  • Fibrosarcoma / therapy*
  • Immunotherapy*
  • Interleukin-2 / immunology*
  • Leukemia, Experimental / immunology
  • Leukemia, Experimental / therapy*
  • Lymphocyte Transfusion*
  • Lymphokines / immunology*
  • Mice
  • Mice, Inbred C57BL
  • Sarcoma, Experimental / immunology
  • Sarcoma, Experimental / therapy*
  • Spleen / immunology
  • Transplantation, Isogeneic


  • Interleukin-2
  • Lymphokines